TP53 and cancer: Finally, we evaluated the activity of AM-9022 in four low-passage TNBC patient-derived xenograft (PDX) tumor models (CTG-0017, CTG-0437, CTG-0888, CTG-1019) that harbored TP53 mutations plus a subset of relevant cancer gene alterations (Supplementary Table 6).